Sanofi Pasteur MSD to Commercialise New 6-in-1 Paediatric Vaccine in European Markets

Lyon, France (ots/PRNewswire) -

Vaccine submitted to European Medicines Agency for
licence review

Sanofi Pasteur MSD plans to licence and commercialise an
innovative 6-in-1 paediatric vaccine in its European territories.

The new hexavalent vaccine, developed by Sanofi Pasteur, is the
only fully liquid, ready to use 6-in-1 vaccine to protect infants
against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B,
poliomyelitis and invasive infections caused by Haemophilus
influenzae type b.

"This is a landmark for our company as we hope to provide
healthcare professionals in Europe with a ready-to-use hexavalent
vaccine that will raise the standard of care in vaccination for
millions of infants," said Jean-Paul Kress, MD, President of Sanofi
Pasteur MSD.

"This clearly reflects our commitment to bring innovative new
vaccines to the European market and it shows the benefits of being
able to draw upon the collective expertise of our joint venture. With
this new 6-in-1 vaccine, Sanofi Pasteur MSD will then have a broad
paediatric vaccine portfolio that will allow us to provide a wide
range of vaccine solutions for our customers."

Sanofi Pasteur MSD is a joint venture in Europe between Sanofi
Pasteur, the vaccines division of Sanofi, and Merck, known as MSD
outside the United States and Canada.

The vaccine has been submitted by Sanofi Pasteur MSD to the
European Medicines Agency (EMA) for licence within the European Union
and upon approval the company will commercialise it in its European
territories under its own brand name.

About Sanofi Pasteur MSD

Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the
vaccine division of Sanofi, and Merck, known as MSD outside the USA
and Canada. Combining innovation and expertise, Sanofi Pasteur MSD is
the only company in Europe dedicated exclusively to vaccines. Sanofi
Pasteur MSD is able to draw on the research expertise of Sanofi
Pasteur and Merck to focus on the development of new vaccines for
Europe to improve the acceptability, efficacy and tolerability of
vaccination.

For further information contact:

Caroline ASHE
Senior Director External Communications Europe
Sanofi Pasteur MSD
Tel : +33-4-37-28-4040
Mob : +33-6-33-46-1365
CAshe@spmsd.com

ots Originaltext: Sanofi Pasteur MSD
Im Internet recherchierbar: http://www.presseportal.de